Analysts Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Target Price at $124.11

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have earned an average recommendation of “Hold” from the twenty-one ratings firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $124.11.

ZBH has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price target for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Truist Financial increased their target price on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Wells Fargo & Company boosted their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Wednesday. Finally, Raymond James lowered their target price on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th.

Zimmer Biomet Stock Down 1.1 %

ZBH opened at $109.36 on Thursday. Zimmer Biomet has a twelve month low of $100.67 and a twelve month high of $133.90. The company’s 50-day moving average price is $107.94 and its two-hundred day moving average price is $108.26. The stock has a market cap of $21.77 billion, a price-to-earnings ratio of 20.79, a PEG ratio of 1.90 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the business earned $1.65 earnings per share. Zimmer Biomet’s revenue for the quarter was up 4.1% on a year-over-year basis. As a group, equities analysts expect that Zimmer Biomet will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.88%. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Institutional Trading of Zimmer Biomet

Several institutional investors and hedge funds have recently made changes to their positions in ZBH. Stonebridge Financial Group LLC bought a new position in shares of Zimmer Biomet during the 4th quarter valued at $25,000. Dunhill Financial LLC increased its holdings in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the period. Ashton Thomas Securities LLC bought a new stake in shares of Zimmer Biomet in the 3rd quarter valued at about $28,000. Bangor Savings Bank purchased a new stake in Zimmer Biomet during the 3rd quarter valued at about $31,000. Finally, Brooklyn Investment Group bought a new position in Zimmer Biomet during the 3rd quarter worth approximately $35,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.